© 1996 British Society for Rheumatology
research-article |
AGALACTOSYL IgG [Gal(o)]—AN ANALYSIS OF ITS CLINICAL UTILITY IN THE LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATOID ARTHRITIS
Department of Immunology
*Centre for Rheumatology /Bloomsbury Rheumatology Unit, University College London
Department of Rheumatology, St Alban's City Hospital
Correspondence to:
Correspondence to: Correspondence to: D. Isenberg, Bloomsbury Rheumatology Unit, Arthur Stanley House, 40–50 Tottenham Street, London W1P 9PG
This long-term prospective study of patients with newly diagnosed RA assesses the relative value of certain clinical and laboratory measures at first consultation in order to determine factors that help to discriminate between patients likely to go into early remission and those with relapsing/remitting or persistent disease. Validation was sought in a similar group from a separate but comparable prospective study. Measures of clinical activity such as joint score, early morning stiffness (EMS) and acute phase (ESR) improved over 4 yr in both groups, whereas agalactosyl IgG [Gal(o)] levels increased. Using discriminant functional analysis in the first cohort to identify features at entry which would predict outcome at 4 yr, a combination of Gal(o), grip strength, age at onset and gender predicted the course of RA correctly in 95% of the patients. This combination was confirmed in the second cohort, although with reduced power (78% correct). Thus, we show that Gal(o) does not reflect activity of the disease like the ESR, but has greater potential as a prognostic index early in the course of disease.
KEY WORDS: Agalactosyl IgG, Rheumatoid arthritis, Prediction of disease outcome